Lund, Sweden and Princeton, New Jersey (ots/PRNewswire) - New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorder Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals today announced positive top-line results from a long-term ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - - In this pooled analysis of 12 studies, a plateau in the survival curve begins at approximately three years, with some patients followed for up to ten years - Three-year estimated survival rate of 22% observed in patients treated with ipilimumab - Findings are based on ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - Intended only for European media based outside of the UK - 53% response rate observed in patients receiving 1 mg/kg nivolumab plus 3 mg/kg Yervoy concurrently (n= 9 of 17), the dose used in the Phase 3 trial; of these responders all experienced at least 80% tumor shrinkage ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - - This all-oral treatment regimen is being studied as an interferon-free and ribavirin-free option - Investigational regimen involves three different classes of direct-acting antivirals (DAAs) - an NS5A replication complex inhibitor, an NS3 protease inhibitor and an NS5B ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - - Long-Term Follow Up From Phase 3 Study (024) Demonstrated That 19.0 Percent of Treatment-Naïve Patients Who Received YERVOY at Investigational Dose of 10 mg/kg Plus Dacarbazine (DTIC) Were Alive at Four Years vs. 9.6 Percent of Patients Treated with DTIC Alone - Few New ...